ArticleGynecologic oncology2022
Pre-treatment inflammatory parameters predict survival from endometrial cancer: A prospective database analysis.
Article in Gynecologic oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 5 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Pooled it
- Pooled it
- Prognostic value of pretreatment systemic immune-inflammation index in patients with endometrial cancer: a meta-analysis.Biomarkers in medicine · 2024Pooled it
- Prognostic role of C-reactive protein in patients with endometrial cancer: a meta-analysis.Biomarkers in medicine · 2024Pooled it
- C-Reactive Protein as a Prognostic Biomarker for Gynecologic Cancers: A Meta-Analysis.Computational intelligence and neuroscience · 2022Pooled it
- Platelet-to-Lymphocyte Ratio as a Predictor of Lymphovascular Space Invasion in Endometrioid Endometrial Cancer: Development and Internal Validation of a Continuous Parameter-Based Nomogram.Medicina (Kaunas, Lithuania) · 2026Article
- Review
- Clinical significance of MIF in predicting lymph node metastasis and immune-inflammatory characteristics in endometrial cancer: a retrospective study of 361 patients.American journal of translational research · 2026Article
- Age, lifestyle, and disease affect ciliary transport in the human fallopian tube.Scientific reports · 2025Article
- Novel screening model for infectious mononucleosis in febrile pediatric patients using a 3D-DIFF scattergram.BMC infectious diseases · 2025Article
- The systemic immune-inflammation index in the efficacy prediction of neoadjuvant chemotherapy in patients with endometrial cancer.Translational cancer research · 2025Article
- The Predictive Role of Neutrophil Percentage-to-Albumin Ratio (NPAR) in Endometrial Carcinoma: A Novel Prognostic Marker.International journal of women's health · 2025Article
- The prognostic value of pretreatment inflammatory and nutrition-related indices in patients with cardia cancer.Frontiers in nutrition · 2025Article
- A potential inflammatory biomarker for advanced endometrial cancer treated with lenvatinib plus pembrolizumab.The journal of obstetrics and gynaecology research · 2025Article
- Observational
- The predictive value of NLR, PLR and MLR in the differential diagnosis of benign uterine diseases and endometrial malignant tumors.Discover oncology · 2024Article
- Evaluation of factors predicting the benefit from systemic oncological treatment for severely ill hospitalized patients: a retrospective study.BMC palliative care · 2023Observational
- Development and validation of a CT radiomics and clinical feature model to predict omental metastases for locally advanced gastric cancer.Scientific reports · 2023Article
- Phytochemical screening ofFrontiers in nutrition · 2023Article
- Pembrolizumab plus lenvatinib in advanced endometrial cancer: case report and systematic review of lung toxicity.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
Abstract
purposeInflammation predisposes to tumorigenesis by damaging DNA, stimulating angiogenesis and potentiating pro-proliferative and anti-apoptotic processes. The aim of this study was to investigate whether pre-treatment biomarkers of systemic inflammation are associated with survival outcomes in endometrial cancer. PATIENTS AND
methodsWomen with endometrial cancer were recruited to a prospective database study. Pre-treatment systemic markers of inflammation, including C-reactive protein (CRP), Glasgow Prognostic Score and lymphocyte-based ratios [neutrophil-lymphocyte ratio (NMR), monocyte-lymphocyte ratio (MLR), systemic immune-inflammation index (SII)], were analysed in relation to overall, endometrial cancer-specific and recurrence-free survival using Kaplan-Meier estimation and multivariable Cox regression.
resultsIn total, 522 women of mostly White British ethnicity, with a median age of 66 years (interquartile range (IQR), 56, 73) and BMI of 32 kg/m
conclusionIf confirmed in an independent cohort, CRP may offer a simple, low-cost test to refine pre-treatment risk assessment and guide personalised care in endometrial cancer. Our participants were mostly of White British ethnicity and further studies are needed to confirm the utility of CRP as a prognostic biomarker in other populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.